Pablo Altman

Statistics

Publications

Citations

346

H-Index

Active since

2014

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Tris Pharma (United States)

University of Toronto

University Medical Center Groningen

Pablo Altman is an author at Novartis (United States) specializing in pulmonology, chronic obstructive pulmonary disease, and pulmonary function testing.

ORCID

Publications per year

2014–2022

Publications

INSTEAD: a randomised switch trial of indacaterol <i>versus</i> salmeterol/fluticasone in moderate COPD

Andrea Rossi, Thys van der Molen, Ricardo del Olmo et al. · European Respiratory Journal · 2014 · 122 citations · Full text

Pharmacy, Pharmacotherapy, Pulmonary Function Testing +16

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

Pablo Altman, Luis Wehbe, Juergen Dederichs et al. · BMC Pulmonary Medicine · 2018 · 69 citations · Full text

Medicine, Pharmacotherapy, Respiratory Therapy +17

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Christopher M. Blanchette, Nicholas J. Gross, Pablo Altman · PubMed · 2014 · 41 citations · Full text

Medicine, Internal Medicine, Pharmacoeconomics +17

Uncontrolled asthma across GINA treatment steps 2 − 5 in a large US patient cohort

William W. Busse, Juanzhi Fang, Jessica Marvel et al. · Journal of Asthma · 2021 · 30 citations · Full text

Medicine, Internal Medicine, Allergy +12

Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)

Philippe Gevaert, Claus Bachert, Jorge Máspero et al. · Journal of Allergy and Clinical Immunology · 2022 · 22 citations

Medicine, Pharmacology, Pharmacotherapy +9

1–5 of 9